Sclerotherapy

Closure follows a linked biological sequence rather than occurring immediately after injection. The sclerosant irritates the vessel’s endothelial lining, which triggers inflammation and blood clot formation. Over time, fibrosis develops within the treated vessel and seals it. This staged response explains why the clinical effect includes both vessel closure and gradual reduction of its visibility.

Sclerotherapy may use either a liquid or foam sclerosant formulation. The provided clinical context does not assign one formulation to every vessel type, so selection is individualized according to the vessel’s size and location, along with patient factors. Recognizing these formulation options allows clinicians to tailor treatment rather than applying one approach uniformly.

Treatment selection depends on several clinical characteristics, especially the size and location of the vessel and factors specific to the patient. These considerations help determine whether injection treatment is suitable and which approach may be most appropriate. They also influence whether ultrasound guidance or a liquid or foam formulation should be considered for targeting the abnormal vessel.

A clinician first evaluates the target vessel and considers its size, location, and relevant patient factors. The selected sclerosant, provided as a liquid or foam, is then injected into the vessel. When the target lies deeper, ultrasound guidance can improve localization and targeting, helping the clinician direct treatment toward the intended vessel.

Clinical applications include varicose veins, spider veins, and selected vascular lesions. The treatment can address both visible superficial veins and, when appropriate, deeper vessels targeted with ultrasound guidance. Its role is therefore broader than cosmetic vein reduction alone, extending to selected aspects of venous disease and abnormal vascular lesions.

Sclerotherapy can reduce the visibility of unwanted veins and relieve related symptoms. As the treated vessel closes, blood flow is redirected toward healthier veins, while the sealed vessel undergoes fibrosis. Results depend on appropriate treatment selection, including consideration of vessel size, location, and patient factors, so outcomes are not identical for every vascular problem.